Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

About this update from Fennec Pharmaceuticals Inc.

RESEARCH TRIANGLE PARK - Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026 . Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail Date: Thursday, May 14, 2026 Time: 8:30 a.m. Eastern Time Webcast Link: https://edge.media-server.com/mmc/p/2iptdco4 Participant Link: https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3 To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days. About Fennec Pharmaceuticals Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI. In March 2024 , Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd. , a leading European specialist pharmaceutical company, will commercialize PEDMARQSI in Europe , U.K. , Australia and New Zealand . PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe , which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally. Contact: Robert Andrade Tel: +1 919-246-5299 Lindsay Rocco Tel: +1 862-596-1304 Email: [email protected] (C) 2026 Electronic News Publishing, source ENP Newswire

View stock analysis, news, and events for Fennec Pharmaceuticals Inc.